BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 23701429)

  • 21. CD138 (syndecan-1) expression in bone-forming tumors.
    Nunez AL; Siegal GP; Reddy VV; Wei S
    Am J Clin Pathol; 2012 Mar; 137(3):423-8. PubMed ID: 22338054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SATB2 Expression in Undifferentiated Pleomorphic Sarcomas of Bone.
    Warmke LM; Maloney N; Leung CH; Lin H; Lazar AJ; Wang WL
    Am J Clin Pathol; 2022 Aug; 158(2):235-241. PubMed ID: 35311957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synovial sarcoma with extensive osteoid and bone formation.
    Milchgrub S; Ghandur-Mnaymneh L; Dorfman HD; Albores-Saavedra J
    Am J Surg Pathol; 1993 Apr; 17(4):357-63. PubMed ID: 7684201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
    Ud Din N; Umer M; Park YK
    Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
    [No Abstract]   [Full Text] [Related]  

  • 25. Lentiviral-mediated expression of SATB2 promotes osteogenic differentiation of bone marrow stromal cells in vitro and in vivo.
    Gong Y; Qian Y; Yang F; Wang H; Yu Y
    Eur J Oral Sci; 2014 Jun; 122(3):190-7. PubMed ID: 24666017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative proteomics analysis of human osteosarcomas and benign tumor of bone.
    Li Y; Liang Q; Wen YQ; Chen LL; Wang LT; Liu YL; Luo CQ; Liang HZ; Li MT; Li Z
    Cancer Genet Cytogenet; 2010 Apr; 198(2):97-106. PubMed ID: 20362224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling.
    Xu HY; Fang W; Huang ZW; Lu JC; Wang YQ; Tang QL; Song GH; Kang Y; Zhu XJ; Zou CY; Yang HL; Shen JN; Wang J
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4516-4528. PubMed ID: 29131265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.
    Wojcik JB; Bellizzi AM; Dal Cin P; Bredella MA; Fletcher CD; Hornicek FJ; Deshpande V; Hornick JL; Nielsen GP
    Am J Surg Pathol; 2014 Nov; 38(11):1538-44. PubMed ID: 24921641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOS Expression in Osteoid Osteoma and Osteoblastoma: A Valuable Ancillary Diagnostic Tool.
    Amary F; Markert E; Berisha F; Ye H; Gerrand C; Cool P; Tirabosco R; Lindsay D; Pillay N; O'Donnell P; Baumhoer D; Flanagan AM
    Am J Surg Pathol; 2019 Dec; 43(12):1661-1667. PubMed ID: 31490237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SATB2 and TLE1 Expression in BCOR-CCNB3 (Ewing-like) Sarcoma, Mimicking Small Cell Osteosarcoma and Poorly Differentiated Synovial Sarcoma.
    Creytens D
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):e10-e12. PubMed ID: 29084055
    [No Abstract]   [Full Text] [Related]  

  • 31. Expression of E-cadherin in bone and soft tissue sarcomas: a possible role in epithelial differentiation.
    Sato H; Hasegawa T; Abe Y; Sakai H; Hirohashi S
    Hum Pathol; 1999 Nov; 30(11):1344-9. PubMed ID: 10571515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SATB2 is not a reliable diagnostic marker for distinguishing between oral osteosarcoma and fibro-osseous lesions of the jaws.
    Grad-Akrish S; Rachmiel A; Ben-Izhak O
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 May; 131(5):572-581. PubMed ID: 33309262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
    Dohi O; Ohtani H; Hatori M; Sato E; Hosaka M; Nagura H; Itoi E; Kokubun S
    Histopathology; 2009 Oct; 55(4):432-40. PubMed ID: 19817894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What's new in bone forming tumours of the skeleton?
    Franceschini N; Lam SW; Cleton-Jansen AM; Bovée JVMG
    Virchows Arch; 2020 Jan; 476(1):147-157. PubMed ID: 31741049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation.
    Dobreva G; Chahrour M; Dautzenberg M; Chirivella L; Kanzler B; Fariñas I; Karsenty G; Grosschedl R
    Cell; 2006 Jun; 125(5):971-86. PubMed ID: 16751105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sclerostin expression in skeletal sarcomas.
    Shen J; Meyers CA; Shrestha S; Singh A; LaChaud G; Nguyen V; Asatrian G; Federman N; Bernthal N; Eilber FC; Dry SM; Ting K; Soo C; James AW
    Hum Pathol; 2016 Dec; 58():24-34. PubMed ID: 27498059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
    Bellizzi AM
    Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone formation: The nuclear matrix reloaded.
    Ellies DL; Krumlauf R
    Cell; 2006 Jun; 125(5):840-2. PubMed ID: 16751095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sclerosing epithelioid fibrosarcoma of bone: morphological, immunophenotypical, and molecular findings of 9 cases.
    Kosemehmetoglu K; Ardic F; Kilpatrick SE; Aydingoz U; Sumathi VP; Michal M
    Virchows Arch; 2021 Apr; 478(4):767-777. PubMed ID: 33084978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.